论文部分内容阅读
目的观察替加色罗治疗便秘型肠易激综合征(C-IBS)的疗效及其对血浆P物质(SP)的调节作用。方法将56例符合罗马Ⅱ诊断标准的C-IBS患者随机分成两组,每组28例。治疗组给予替加色罗,6 mg,每天2次,对照组给予谷维素10 mg,每天2次,治疗4周。在治疗前后,运用放射免疫法测定两组血浆SP浓度。结果治疗组总有效率89.29%,显著优于对照组(P<0.05);治疗组能显著升高血浆SP浓度,与对照组比较差异有统计学意义。结论替加色罗治疗C-IBS疗效确切;通过升高血浆SP浓度间接地达到调节肠道的异常机械运动是其作用机制之一。
Objective To observe the curative effect of tegaserod on constipation-induced irritable bowel syndrome (C-IBS) and its regulation on plasma substance P (SP). Methods Fifty-six patients with C-IBS meeting the diagnostic criteria of Rome Ⅱ were randomly divided into two groups of 28 cases. The treatment group was given tegaserod, 6 mg twice daily, while the control group was given 10 mg oryzanol twice daily for 4 weeks. Before and after treatment, radioimmunoassay was used to determine plasma SP concentration in both groups. Results The total effective rate of the treatment group was 89.29%, which was significantly better than that of the control group (P <0.05). The treatment group could significantly increase the plasma SP concentration, which was significantly different from the control group. CONCLUSION: Tegaserod is effective in treating C-IBS. It is one of the mechanisms of action that indirectly regulating the intestinal motility by elevating plasma SP concentration.